Articles

This article summarizes the social media accomplishments -- despite bumps in along the way -- that earned the Boehringer Ingelheim (BI) Global Social Media Team the coveted Pharmaguy Social Media Pioneer Award.

This article summarizes the comments from a LinkedIn debate and #mHealthPharma TweetChat and condenses the learnings into one simple formula for creating quality pharma mHealth apps.

Welcome to Volume 13, Issue #9 (OCTOBER 2014) of Pharma Marketing News.

This article summarizes some of the main points made by PhRMA, Washington Legal Foundation (WLF), BIO, Medical Information Working Group (MIWG), Patient, Consumer, and Public Health Coalition, and several pharmaceutical companies, regarding FDA's Draft Guidance on using Internet and social media platforms with character space limitations.

Welcome to Volume 13, Issue #8 (SEPTEMBER 2014) of Pharma Marketing News.

This article asks the question: Can anecdotal 'evidence'/experiences mentioned in patient videos -- even unbranded videos -- cause unnecessary visits to the doctor's office and over prescribing of drugs with serious side effects?

This reviews FDA's recommendations for distributing reprints that convey 'new risk information' for approved drugs.

Welcome to Volume 13, Issue #7 (AUGUST 2014) of Pharma Marketing News.

Sooner or later Congress, perhaps urged on by patient advocates or some mhealth app adverse event, may investigate the mobile health app industry -- including the drug industry -- to see if further oversight, not just FDA regulations, is required. Before that happens and to ensure that mobile health apps developed by pharma are of the highest quality, the industry should differentiate itself from "wild west" developers by being pro-active in developing and abiding by a set of 'Guiding Principles for Mobile Health Apps.'

These days, patient storytelling is all the rage. More often than not, however, patient stories told by pharma marketers are not 'providing truth' in the sense that they are real patient stories.